Antiretroviral prophylaxis: a defining moment in HIV control
- PMID: 21771566
- PMCID: PMC3253379
- DOI: 10.1016/S0140-6736(11)61136-7
Antiretroviral prophylaxis: a defining moment in HIV control
Conflict of interest statement
We were the co-Principal Investigators of the CAPRISA 004 trial of tenofovir gel. QAK is co-Principal Investigator of the HIV Prevention Trials Network, which is undertaking HPTN 052 trial of treatment for prevention. SSAK is an executive committee member of the Microbicide Trials Network, which is undertaking VOICE trial of oral and topical PrEP.
Figures
References
-
- Partners PrEP study press release. Pivotal study finds that HIV medications are highly effective as prophyalxis against HIV infection in men and women in Africa. 2011. [accessed July 13, 2011]. http://depts.washington.edu/uwicrc/research/studies/files/PrEP_PressRele....
-
- Centers for Diseases Control and Prevention. [accessed July 13, 2011];CDC trial and another major study find PrEP can reduce risk of HIV infection among heterosexuals. 2011 July 13; http://www.cdc.gov/nchhstp/newsroom/PrEPHeterosexuals.html.
-
- HPTN 052 press release. [accessed May 12, 2011];Initiation of antiretroviral treatment protects uninfected sexual partners from HIV infection (HPTN Study 052) 2011 http://www.hptn.org/web%20documents/PressReleases/HPTN052PressReleaseFIN....
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical